Drugs / AST-301(pNGVL3-hICD)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05163223 | Feb 2022 → May 2024 | breast cancer | Aston Sci. Inc. | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AST-301(pNGVL3-hICD) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05163223 ↗ |
| Modality | Vaccine | “therapeutic cancer vaccine (AST-301, pNGVL3-hICD)” NCT05163223 ↗ |
| Route | Other | “Intradermal injection” NCT05163223 ↗ |